Selective myotropic antispasmodic mebeverine in functional gastrointestinal disorders

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Functional gastrointestinal disorders (FGID) are considered a very common pathology that has a significant impact on the quality of life of patients, with involvement of a number of pathogenetic factors in its development. The main and most common diseases in this group include functional dyspepsia (FD) and irritable bowel syndrome (IBS). The purpose of the work is evaluation of the efficacy and safety of one of the well-known antispasmodics, mebeverine, in the treatment of functional gastrointestinal disorders. The review article discusses the pathophysiological mechanisms of the development of FD and IBS, primarily dysmotility of different parts of the gastrointestinal tract, visceral hypersensitivity, disorders of the intestinal microbiome, etc. The data of numerous clinical trials on mebeverine hydrochloride, a myotropic antispasmodic with a direct effect on intestinal muscle activity, are presented. Mebeverine in clinical studies demonstrated a pronounced antispastic activity, safety and good tolerability. Its ability to positively influence the quality of life of patients is especially emphasized. The article also focuses on the drug niaspam with the active substance mebeverine, clinical data on its use in functional pathology of the gastrointestinal tract. It is concluded that mebeverine remains a necessary tool in the treatment of functional gastrointestinal disorders.

Full Text

Restricted Access

About the authors

Sergey A. Bulgakov

Pirogov Russian National Research Medical University

Author for correspondence.
Email: professorbulgakov@gmail.com
ORCID iD: 0000-0002-9004-9400

Dr. Sci. (Med.), Professor at the Department of Gastroenterology, Faculty of Postgraduate Professional Education, Professor at the Department of Biomedical Research, Medical and Biological Faculty

Russian Federation, Moscow

References

  1. Успенский Ю.П., Фоминых Ю.А., Барышникова.Н.В. Функциональная диспепсия и синдром раздраженной кишки: особенности комплексного лечения. Медицинский алфавит. 2017,3;27(324):1–4. [Uspensky Yu.P., Fominykh Yu.A., Baryshnikova.N.V. Functional dyspepsia and irritable bowel syndrome: features of complex treatment. Meditsinskii alfavit. 2017.3;27(324):1–4. (In Russ.)].
  2. Гастроэнтерология и гепатология: диагностика и лечение: руководство для врачей. Под ред. Калинина А.В., Логинова А.Ф., Хазанова А.И. М.: 2011. 864 с. [Gastroenterology and hepatology: diagnosis and treatment: a guide for physicians. Ed. By Kalinin A.V., Loginov A.F., Khazanov A.I. M.: 2011. 864 p.(In Russ.)].
  3. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Воспаление, нарушение моторной функции и висцеральная гиперчувствительность: основные механизмы функциональных расстройств желудочно-кишечного тракта (обзор литературы и резолюция Совета Экспертов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;1:7–14. [Ivashkin V.T., Ma- ev I.V., Trukhmanov A.S. Inflammation, impaired motor function and visceral hypersensitivity: the main mechanisms of functional disorders of the gastrointestinal tract (literature review and resolution of the Council of Experts). Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2022;1:7–14. (In Russ.)].
  4. Drossman D.A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;150:262–79. doi: 10.1053/j.gastro.2016.02.032.
  5. Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N Engl J Med. 2017; 376(26):2566–78. doi: 10.1056/NEJMra1607547.
  6. Ивашкин В.Т., Полуэктова Е.А., Рейхарт Д.В. и др. Эффективность наиболее часто назначаемых групп препаратов у пациентов с функциональными расстройствами желудочно-кишечного тракта – синдромом функциональной диспепсии и синдромом раздражённого кишечника (Результаты наблюдательного исследования). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):14–23. [Ivashkin V.T., Poluektova E.A., Reyhart D.V. Efficacy of the most commonly prescribed groups of drugs in patients with functional disorders of the gastrointestinal tract - functional dyspepsia syndrome and irritable bowel syndrome (Results of an observational study). Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016;26(4):14–23. (In Russ.)].
  7. Карева Е.Н. Фармакология спазмолитических средств, применяемых в терапии синдрома раздражённого кишечника. Доктор.Ру. 2021;20(4):46–54. [Kareva E.N. Pharmacology of antispasmodics used in the treatment of irritable bowel syndrome. Doctor.Ru. 2021;20(4):46–54. (In Russ.)].
  8. Linder A., Selzer H., Classen V. Pharmacological properties of mebeverine, a smooth-muscle relaxant. Arch Int Pharmacodyn Ther. 1963;145:378–95.
  9. Бутов М.А., Шурпо Е.М., Кузнецов П.С., Загравская Н.А. Медикаментозная коррекция дискинезий кишечника. Медицинский совет. 2016;14:42–5. [Butov M.A., Shurpo E.M., Kuznetsov P.S., Zagravskaya N.A. Drug correction of intestinal dyskinesias. Meditsinskii sovet. 2016;14:42–5.(In Russ.)].
  10. Маев И.В., Самсонов А.А., Голубев Н.Н. и др. Эффективность мебеверина в лечении функциональных расстройств желчевыводящих путей. Фарматека. 2011;2:78–84. [Maev I.V., Samsonov A.A., Golubev N.N., et al. Efficiency of mebeverine in the treatment of functional disorders of the biliary tract. Farmateka. 2011;2:78–84. (In Russ.)].
  11. Степанова Е.В., Лоранская И.Д., Ракитская Л.Г., Мамерова Л.Д. Билиарные дисфункции. Эффективность спазмолитической терапии. Эффективная фармакотерапия. 2020;16(1):62–8. [Stepanova E.V., Loranskaya I.D., Rakitskaya L.G., Mamerova L.D. Biliary dysfunction. The effec-tiveness of antispasmodic therapy. Effektivnaya farmakoterapiya. 2020;16(1):62–8. (In Russ.)].
  12. Минушкин О.Н., Масловский Л.В., Львова Н.В. и др. Билиарная дисфункция (в свете рекомендаций Рим – lV): диагностика, лечение. Медицинский алфавит. 2020;10:5–10.[Minushkin O.N., Maslovsky L.V., Lvova N.V. Biliary dysfunction (in the light of Rome-lV recommendations): diagnosis, treatment. Meditsinskii alfavit. 2020;10:5–10. (In Russ.)].
  13. Минушкин О.Н. Фармакологические подходы к лечению сочетанной функциональной патологии (билиарной и кишечника). Медицинский совет. 2018;14:78–82. [Minushkin O.N. Pharmacological approaches to the treatment of combined functional pathology (biliary and intestinal). Meditsinskii sovet. 2018;14:78–82. (In Russ.)].
  14. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;100(5):1174–84. doi: 10.1046/j.1365-2036.2001.00937.x.
  15. Connell A.M. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J. 1965;2(5466):848–51. doi: 10.1136/bmj.2.5466.848.
  16. Lu C.L., Chen C.Y., Chang F.Y., et al. Effect of a calcium channel blocker and antispasmodic in diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000;15(8):925–30. doi: 10.1046/j.1440-1746.2000.02230.x.
  17. Lee K.J., Kim N.Y., Kwon J.K., et al. Efficacy of ramosteron in the treatment of male patients with diarrheа: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23(12):1098–104. doi: 10.1111/j.1365-2982.2011.01771.x.
  18. Boisson J., Coudert P., Dupuis J., et al. Tolerance de la mebeverine a long terme. Act Ther. 1987;16:289–92.
  19. Агафонова Н.А., Назарбекова Р.С., Яковен- ко А.В., Яковенко Э.П. Эффективность мебеверина гидрохлорида в коррекции моторных нарушений кишечника. Русский медицинский журнал. Болезни органов пищеварения.2005;2:101–04. Agafonova N.A., [Nazarbekova R.S., Yakovenko A.V., Yakovenko E.P. T he effectiveness of mebeverine hydrochloride in the correction of intestinal motor disorders. Russkii meditsinskii zhurnal. Bolezni organov pishchevareniya.2005;2:101–04. In Russ.)].
  20. Kennedy T., Jones R., Darnley S., et al. Cognitive behavior in addition to antispasmodic treatment for irritable bowel syndrome in primary care randomized controlled trial. BMJ. 2005;331(7514):435. doi: 10.1136/bmj.38545.505764.06.
  21. Muller-lissner S.A., Kaats V., Brandt W., et al. The perceived effect of various foods and bevereges on stool consistency. Eur J Gastroenterol Hepatol. 2005;17(1):109–12. doi: 10.1097/00042737-200501000-00020.
  22. Evans P.R., Bak Y.T., Kellow J.E. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol. 1996;10:787–93. doi: 10.1046/j.1365-2036.1996.61203000.x.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies